Literature DB >> 8097367

Do tocolytic agents stop preterm labor? A critical and comprehensive review of efficacy and safety.

K Higby1, E M Xenakis, C J Pauerstein.   

Abstract

OBJECTIVE: Our aim was to determine the efficacy and safety of tocolytic agents currently used to treat premature labor. STUDY
DESIGN: We carried out a comprehensive review of tocolytic agents in the treatment of premature labor. Three hundred twenty-eight studies published between 1933 and 1992 were analyzed.
RESULTS: An analysis of randomized, placebo-controlled, clinical trials showed that magnesium sulfate is not better than placebo in the treatment of premature labor. beta-Adrenergic receptor agonists effectively stop premature labor for only 24 to 48 hours. Calcium channel blockers and oxytocin antagonists inhibit uterine contractions, but their role in stopping labor is undefined. Prostaglandin inhibitors appear to be effective in treating premature labor and have few adverse side effects.
CONCLUSIONS: The only tocolytic drugs that might be effective are the prostaglandin inhibitors. Tocolytic agents should be used only between 24 and 32 completed weeks of gestation. Magnesium sulfate should not be used to treat premature labor. Oxytocin antagonists should be used only in experimental clinical trials. Calcium channel blockers and beta-adrenergic receptor agonists inhibit uterine contractions but do not prolong gestation for longer than 48 hours.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097367     DOI: 10.1016/0002-9378(93)90376-t

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  11 in total

1.  Evaluation of a community-wide preterm birth prevention program.

Authors:  H M Scott; K O O'Connor; P A Carr
Journal:  Can J Public Health       Date:  2001 Sep-Oct

2.  A preterm birth prevention project in Nova Scotia, Canada.

Authors:  B A Armson; L Dodds; C Cervin; S Christie-Haliburton; K Rinaldo
Journal:  Matern Child Health J       Date:  2001-09

Review 3.  Management of preterm labour.

Authors:  S Vause; T Johnston
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-09       Impact factor: 5.747

Review 4.  Pharmacokinetics of tocolytic agents.

Authors:  Vassilis Tsatsaris; Dominique Cabrol; Bruno Carbonne
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

5.  A novel optical method to assess cervical changes during pregnancy and use to evaluate the effects of progestins on term and preterm labor.

Authors:  Ruben J Kuon; Shao-Qing Shi; Holger Maul; Christof Sohn; James Balducci; Leili Shi; Robert E Garfield
Journal:  Am J Obstet Gynecol       Date:  2011-02-23       Impact factor: 8.661

6.  Human thioredoxin-1 attenuates the rate of lipopolysaccharide-induced preterm delivery in mice in association with its anti-inflammatory effect.

Authors:  Fumihiko Namba; Mikiko Kobayashi-Miura; Taro Goda; Yukiko Nakura; Fumiko Nishiumi; Aoi Son; Akio Kubota; Junji Yodoi; Itaru Yanagihara
Journal:  Pediatr Res       Date:  2016-04-21       Impact factor: 3.756

Review 7.  Atosiban for preterm labour.

Authors:  Vassilis Tsatsaris; Bruno Carbonne; Dominique Cabrol
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Prenatal exposure to β2-adrenergic receptor agonists and risk of autism spectrum disorders.

Authors:  Lisa A Croen; Susan L Connors; Marilyn Matevia; Yinge Qian; Craig Newschaffer; Andrew W Zimmerman
Journal:  J Neurodev Disord       Date:  2011-08-27       Impact factor: 4.025

9.  The Effects of Progesterone Therapy on the Gestation Length and Reduction of Neonatal Complications in Patients who had Received Tocolytic Therapy for Acute Phase of Preterm Labor.

Authors:  Marzie Lotfalizadeh; Nayereh Ghomian; Amirreza Reyhani
Journal:  Iran Red Crescent Med J       Date:  2013-10-05       Impact factor: 0.611

10.  A double-blinded, randomized, placebo-controlled trial assessing the effects of nifedipine on embryo transfer: Study protocol.

Authors:  Kelvin Kl Ng; Genia Rozen; Tanya Stewart; Franca Agresta; Alex Polyakov
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.